Literature DB >> 23707673

Tailoring systematic lymphadenectomy in high-risk clinical early stage endometrial cancer: the role of 18F-FDG PET/CT.

Cinzia Crivellaro1, Mauro Signorelli, Luca Guerra, Elena De Ponti, Cecilia Pirovano, Robert Fruscio, Federica Elisei, Luca Montanelli, Alessandro Buda, Cristina Messa.   

Abstract

OBJECTIVES: To evaluate the role of FDG PET/CT in the preoperative N-staging of high-risk clinical stage I endometrial cancer. The correlation between the metabolic characteristics of endometrial tumor uptake as predictors of a) lymph-node (LN) metastases and b) recurrence, was also evaluated.
METHODS: Seventy-six high-risk (G2 with deep myometrial invasion, G3, serous/clear-cell carcinoma) clinical stage I endometrial cancer patients underwent preoperative PET/CT scan followed by total hysterectomy, bilateral salpingo-oophorectomy and lymphadenectomy. PET/CT images were analyzed and correlated to histological findings. Maximal and mean standardized uptake value (SUVmax, SUVmean), metabolic tumor volume (MTV), total lesion glycolysis (TLG, defined as the product between SUVmean and MTV) of endometrial lesions were calculated and correlated to: a) presence of LN metastases, b) recurrences.
RESULTS: PET/CT resulted positive at LNs in 12/76 patients: 11/12 truly positive, 1/12 falsely positive. Conversely PET/CT was negative in 64/76 patients: 61/64 truly negative and 3/64 falsely negative. On pt-based analysis, sensitivity, specificity, accuracy, positive and negative predictive value of PET/CT in detecting LN metastases were 78.6%, 98.4%, 94.7%, 91.7%, 95.3%, respectively. A significant association was found between the presence of LN metastases and SUVmax (p=0.038), MTV (p=0.007), TLG (p=0.003) of the primary tumor. No correlations were found between the metabolic parameters and relapse (median follow-up 25.4months).
CONCLUSIONS: In high-risk clinical stage I endometrial cancer FDG PET/CT demonstrated moderate sensitivity, high specificity and accuracy for the nodal status assessment. SUVmax, MTV and TLG of the primary tumor are significantly correlated to LN metastases, while none of these parameters is predictor of recurrence.
Copyright © 2013 Elsevier Inc. All rights reserved.

Entities:  

Keywords:  Endometrial cancer; High-risk; PET/CT; Staging

Mesh:

Substances:

Year:  2013        PMID: 23707673     DOI: 10.1016/j.ygyno.2013.05.011

Source DB:  PubMed          Journal:  Gynecol Oncol        ISSN: 0090-8258            Impact factor:   5.482


  16 in total

1.  Preoperative risk stratification using metabolic parameters of (18)F-FDG PET/CT in patients with endometrial cancer.

Authors:  Kazuhiro Kitajima; Yuko Suenaga; Yoshiko Ueno; Tetsuo Maeda; Yasuhiko Ebina; Hideto Yamada; Takashi Okunaga; Kazuhiro Kubo; Keitarou Sofue; Tomonori Kanda; Yukihisa Tamaki; Kazuro Sugimura
Journal:  Eur J Nucl Med Mol Imaging       Date:  2015-04-02       Impact factor: 9.236

2.  Role of Positron Emission Tomography/Computed Tomography in Preoperative Assessment of Carcinoma Endometrium-a Retrospective Analysis.

Authors:  Rohini Kulkarni; Rani Akhil Bhat; Vibhawari Dhakharia; Kumar Kallur; Aparna Gangoli
Journal:  Indian J Surg Oncol       Date:  2018-11-20

3.  Diagnostic Accuracy of Clinical Biomarkers for Preoperative Prediction of Lymph Node Metastasis in Endometrial Carcinoma: A Systematic Review and Meta-Analysis.

Authors:  Casper Reijnen; Joanna IntHout; Leon F A G Massuger; Fleur Strobbe; Heidi V N Küsters-Vandevelde; Ingfrid S Haldorsen; Marc P L M Snijders; Johanna M A Pijnenborg
Journal:  Oncologist       Date:  2019-06-11

4.  Prognostic value of lymph node-to-primary tumor standardized uptake value ratio in endometrioid endometrial carcinoma.

Authors:  Hyun Hoon Chung; Gi Jeong Cheon; Jae-Weon Kim; Noh-Hyun Park; Yong Sang Song
Journal:  Eur J Nucl Med Mol Imaging       Date:  2017-08-21       Impact factor: 9.236

5.  Utility of PET/CT to Evaluate Retroperitoneal Lymph Node Metastasis in High-Risk Endometrial Cancer: Results of ACRIN 6671/GOG 0233 Trial.

Authors:  Mostafa Atri; Zheng Zhang; Farrokh Dehdashti; Susanna I Lee; Helga Marques; Shamshad Ali; Wui-Jin Koh; Robert S Mannel; Paul DiSilvestro; Stephanie A King; Michael Pearl; XunClare Zhou; Marie Plante; Katherine M Moxley; Michael Gold
Journal:  Radiology       Date:  2017-01-03       Impact factor: 11.105

Review 6.  Role of pelvic and para-aortic lymphadenectomy in endometrial cancer: current evidence.

Authors:  Giorgio Bogani; Sean C Dowdy; William A Cliby; Fabio Ghezzi; Diego Rossetti; Andrea Mariani
Journal:  J Obstet Gynaecol Res       Date:  2014-02       Impact factor: 1.730

7.  The Accuracy of Integrated [(18)F] Fluorodeoxyglucose-Positron Emission Tomography/Computed Tomography in Detection of Pelvic and Para-aortic Nodal Metastasis in Patients with High Risk Endometrial Cancer.

Authors:  Nikhil Shirish Gholkar; Subhas Chandra Saha; Grv Prasad; Anish Bhattacharya; Radhika Srinivasan; Vanita Suri
Journal:  World J Nucl Med       Date:  2014-09

Review 8.  Role of 18F-FDG PET/CT in the carcinoma of the uterus: a review of literature.

Authors:  Alessandra Musto; Gaia Grassetto; Maria Cristina Marzola; Sotirios Chondrogiannis; Anna Margherita Maffione; Lucia Rampin; David Fuster; Francesco Giammarile; Patrick M Colletti; Domenico Rubello
Journal:  Yonsei Med J       Date:  2014-11       Impact factor: 2.759

Review 9.  What Is the Best Preoperative Imaging for Endometrial Cancer?

Authors:  Ingfrid S Haldorsen; Helga B Salvesen
Journal:  Curr Oncol Rep       Date:  2016-04       Impact factor: 5.075

10.  Gynecologic tumors: how to communicate imaging results to the surgeon.

Authors:  Stefania Rizzo; Giuseppina Calareso; Federica De Maria; Vanna Zanagnolo; Roberta Lazzari; Agnese Cecconi; Massimo Bellomi
Journal:  Cancer Imaging       Date:  2013-12-30       Impact factor: 3.909

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.